Strategic partnership Strong collaboration with Eli Lilly for AI-designed enzymes and recombinases signals substantial enterprise validation and potential for multi-program deals. Leverage Lilly relationship to approach adjacent biopharma players seeking AI-enabled gene editing and protein design capabilities.

AI-first edge Profluent’s focus on AI-driven protein design and large foundation models positions it to offer accelerated discovery timelines and bespoke proteins, appealing to pharma companies aiming to shorten development cycles and outpace competitors with computational design.

Financial momentum Recent high-value deals imply robust revenue potential and investor confidence. Target expansion into mid-to-large cap biopharma and contract research organizations seeking scalable AI design tooling and collaborative research programs.

Global market reach Partnerships and press coverage across multiple regions indicate growing visibility. Pursue international pharma and biotech clients with unmet needs in gene editing, recombinases, and DNA-editing medicines to diversify revenue streams.

Growth opportunities Recent funding and a growing client pipeline create opportunities to upsell governance, dedicated CDX/validation services, and customized model tuning. Develop tiered service plans and add-on modules for earlier and broader adoption among customers.